Cargando…
P1095: TREATMENT ATTRIBUTES FOR 3RD LINE FOLLICULAR LYMPHOMA TREATMENT DECISION-MAKING: PHYSICIAN PERSPECTIVES FROM A SURVEY ACROSS WESTERN EUROPE AND THE UNITED STATES
Autores principales: | Johnson, P. C., Bailey, A., Milloy, N., Clayton, E., Quek, R. G., Ma, Q. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429670/ http://dx.doi.org/10.1097/01.HS9.0000847248.25328.19 |
Ejemplares similares
-
P1095: COVID-19 VACCINE RESPONSES IN FOLLICULAR LYMPHOMA: DETERMINANTS OF HUMORAL AND CELLULAR IMMUNITY IN THE PETREA TRIAL OF FRONTLINE CHEMOIMMUNOTHERAPY
por: Jer Lim, Yeong, et al.
Publicado: (2023) -
Controversies in the Treatment of Follicular Lymphoma
por: Hübel, Kai, et al.
Publicado: (2020) -
Targeted Treatment of Follicular Lymphoma
por: Nath, Karthik, et al.
Publicado: (2021) -
Follicular lymphoma - treatment and prognostic factors
por: Luminari, Stefano, et al.
Publicado: (2012) -
New targets for the treatment of follicular lymphoma
por: Tageja, Nishant, et al.
Publicado: (2009)